Groundbreaking technology shows immense potential for treating ischemic retinopathy

A groundbreaking technology with immense potential in treating ischemic retinopathy in premature infants and diabetic patients has been developed by Professor Byoung Heon Kang and his research team in the Department of Biological Sciences at UNIST, in collaboration with Professor Dong Ho Park’s team at Kyungpook National University Hospital. Ischemic retinopathy, characterized by the breakdown of the blood-retinal barrier and abnormal blood vessel growth, often leads to vision impairment and loss.

Pharmalittle: We’re reading about Novartis losing bid to block a generic, pharma deals, and more

Rise and shine, everyone, another busy day is on the way. Our mascots, for instance, got off to a particularly busy start, having spotted a

August 13, 2024

Janssen seeks EMA approval for RYBREVANT in NSCLC

Share this article The Rybrevant regimen is intended for treating advanced non-small cell lung cancer. Credit: Minerva Studio / Shutterstock.com. The Janssen Pharmaceutical Companies of

February 9, 2024

Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target

Nearly two decades ago, a small company called Amylin Pharmaceuticals saw that its first commercial product, a diabetes treatment targeting receptors of the amylin hormone,

September 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.